Immatics N.V. (IMTX)
About Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $1.3B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.3B
- Shares outstanding
- 147.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 2, 2020
Immatics N.V. (IMTX) Stock Price
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immatics N.V..
Write a review
News about Immatics N.V.
News & sentiment via Polygon.io
Immatics N.V.: frequently asked questions
Is Immatics N.V. an American company?
Immatics N.V. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Immatics N.V. publicly traded?
Yes — Immatics N.V. is a publicly traded company. Its stock trades under the ticker symbol IMTX on the NASDAQ.
What does Immatics N.V. do?
Immatics N.V. is an American Pharmaceuticals company in the Health & Beauty sector.
